Frank Ulrich Montgomery
President of the German Medical Association
Frank Ulrich Montgomery, was elected president of the German Medical Association (GMA) and the German Medical Assembly in June 2011 by the German Medical Assembly. Before assuming this position, he served as vice-president of the GMA from 2007 to 2011. Between 1994 and 2002 and since 2006 he also serves as president of the State Chamber of Physicians of Hamburg. Since 2015 he serves as vice-chairman of the World Medical Association (WMA) and treasurer of the Standing Committee of European Doctors (CPME). Since the 80ies he is also very committed to all ethical matters concerning the medical profession. He continues to work as a specialist and consultant radiologist at the University Hospital in Hamburg since 1986.
Global Head of the TIP Oncology at Merck Serono
Andree Blaukat serves as Senior Vice President and Head of the Translational Innovation Platform Oncology at Merck with responsibility for the Oncology Research portfolio. In this role, he leads a team of about 100 scientists, technicians and support staff in Darmstadt and Boston. Prior to joining Merck, Andree was a junior group leader and lecturer for pharmacology and toxicology at the Institute of Pharmacology of the Ruprecht-Karls-University Heidelberg. Before this assignment he was Postdoctoral Fellow at the Ludwig Institute for Cancer Research in Uppsala, Sweden. He obtained his PhD in biochemistry from the Universities of Mainz & Darmstadt in 1997.
Chairman of the Leuven Cancer Institute
Michel Delforge trained in Leuven and at the University of Minnesota, USA, and obtained a doctoral degree in biomedical sciences. Dr Delforge is currently clinical head at the department of hematology where he directs the plasma cell dyscrasia unit. He is also a senior clinical investigator and a member of the executive committee of the Stem Cell Institute Leuven. He is chairman of the Myeloma Working Group of the Belgian Hematological Society and an active member of the IFM, HOVON (Hemato-Oncology Foundation for Adults in The Netherlands), and the International Myeloma Working Group. He holds the Luc Fraiture Chair in Hematology at the University of Leuven, and has authored or co-authored more than 140 manuscripts and several book chapters in the field of hematology.
Katelijne De Nys
Chair of the Belgian Commission for the Reimbursement of Medicines and professor at the KU Leuven
Katelijne De Nys trained as MD in Leuven and serves as a specialist in radiotherapy-oncology (with focus on palliative care) at the University Hospitals Leuven, and holds a PhD in Biomedical Sciences. She has worked for the Belgian Federal Agency for Medicines and Health Products (FAMHP) and for the EMEA (European Medicines Agency, London). Thereafter, she was head of the Medicines unit of the Cabinet of the Belgian Federal Minister of Health & Social Affairs and head of the Clinical Trial Center of the University Hospitals Leuven.
Program Director Life Science Technologies at IMEC
Liesbet Lagae works at IMEC which is a world leader for Research & Development on nanoelectronics and digital technologies. After a PhD in spintronics and magnetic memory technology, she joined IMEC in 2003 where she initiated the field of molecular and cellular biochips. She is the R&D Director and co-founder of IMEC’s strongly expanding life science technology program which provides smart silicon chip solutions to the life science industry. Her role there is to bring new technology and innovation to develop better tools for life sciences. She is also an associate professor at KULeuven in Nanobiophysics.
Co-director VIB-KULeuven Center for Cancer Biology and Head of the Laboratory for Translational Genetics
Diether Lambrechts was trained as an engineer at the University of Leuven and worked under Peter Carmeliet on the role of vascular endothelial growth factor in amyotrophic lateral sclerosis for his PhD and postdoc until 2007. He then worked at the Wellcome Trust Centre for Human Genetics in the Nuffield Department of Clinical Medicine at the University of Oxford, England, before joining VIB as an independent VIB group leader. In 2013, he was awarded an ERC Consolidator grant.
Head of health economics division at the German Cancer Research Center
Michael Schlander is founding chairman of the not-for-profit “Institute for Innovation & Valuation in Health Care” in Wiesbaden (since 2005). In 2008, he was a co-founder of the German Society for Health Economics, and in 2012, he acted as scientific chair for the European ISPOR Congress in Berlin, with more than 3,500 attendants. Schlander studied medicine and psychology at the U of Frankfurt and has been licensed as a physician in Germany since 1985. He received his M.D. from the U of Frankfurt, his MBA from City U of Seattle, Washington, a diploma in health economics from the Stockholm School of Economics (2002), and the venia legendi for health economics from the U of Heidelberg (2007). Prior to returning to academia in 2002, he spent 15 years in executive roles for the international biopharmaceutical industry.
Co-founder and ex-CEO of Ganymed Pharmaceuticals AG
Özlem Türeci is an MD, immunologist and entrepreneur. She is co-founder and Ex-CEO of Ganymed Pharmaceuticals AG, a clinical stage biotech company developing ideal antibody drugs, recently acquired by Astellas. Her research contributed to foundation of BioNTech AG, the technology leader in personalized cancer immunotherapies, and TRON, a non-for-profit research think tank for translation. Özlem is Chairman of Ci3, the German Spitzencluster for Individualized ImmunIntervention e.V. and an executive board member of CIMT, the largest European Association for Cancer Immunotherapy.
Director of Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ)
Olaf Witt’s major interest is the identification of biomarkers for response prediction in precision medicine as well as in developing rationale treatment combination strategies to overcome resistance in pediatric oncology. Since 2015 Olaf Witt is coordinating the (inter)national precision program in pediatric oncology termed “INFORM” (INdividualized Therapy FOr Relapsed Malignancies in Childhood) and is currently developing innovative phase I/II biomarker driven combination trials in pediatric oncology. He is coordinating investigator of the pan-European low grade glioma phase III trial (LOGGIC Europe Trial) study group and elected board member of the German Society of Pediatric Oncology and Hematology (GPOH).